Trodelvy Keytruda Combination Delivers Breakthrough Results in Metastatic Triple-Negative Breast Cancer

By João L. Carapinha

April 30, 2025

A Phase III trial (ASCENT-04/KEYNOTE-D19) has shown that the Trodelvy Keytruda combination improves progression-free survival over Keytruda plus chemotherapy in previously untreated PD-L1-positive metastatic triple-negative breast cancer (mTNBC). This pivotal study is the first to demonstrate superiority for a TROP-2 antibody-drug conjugate combined with an immuno-oncology agent in first-line mTNBC treatment.

Improving Treatment Options

The Trodelvy Keytruda combination marks a groundbreaking approach. It is the first time an antibody-drug conjugate (ADC) paired with immunotherapy has shown potential in early metastatic breast cancer treatment. As Dietmar Berger, Chief Medical Officer at Gilead Sciences, highlights, this therapy could redefine options for patients with this challenging cancer.

The ASCENT-04/KEYNOTE-D19 trial was a global, open-label, randomized study involving 443 patients with untreated, PD-L1-positive (CPS ≥ 10) metastatic TNBC. Participants received either:

  • 10 mg/kg of Trodelvy on days one and eight of a 21-day cycle plus 200 mg of Keytruda on day one, or
  • Chemotherapy (gemcitabine plus carboplatin, paclitaxel, or nab-paclitaxel) combined with Keytruda.

Trodelvy (sacituzumab govitecan-hziy) is an antibody-drug conjugate targeting Trop-2, a protein overexpressed in epithelial cancers. It uses a humanized monoclonal antibody linked to SN-38, the active metabolite of irinotecan, which disrupts topoisomerase I and induces cell death. Unlike conventional chemotherapy, this targeted approach may spare normal cells.

Contextualizing Triple-Negative Breast Cancer

TNBC makes up 10-15% of breast cancer cases. It is hard to treat because it does not respond to hormone or targeted therapies. Current standard treatments give patients only 5-7 months of progression-free survival before disease progression.

In 2020, the FDA approved pembrolizumab (Keytruda) plus chemotherapy for advanced TNBC patients with PD-L1 scores ≥10. This combo improved progression-free survival over chemotherapy alone. Trodelvy is already approved for advanced TNBC patients with at least two prior therapies and for certain metastatic breast cancer cases.

Health Economics and Patient Outcomes

The Trodelvy Keytruda combination improves progression-free survival significantly. This may enhance patients’ quality of life and reduce healthcare use linked to disease progression. If long-term data show better overall survival, its value could grow further.

Gilead will present detailed study results soon and engage with regulators. The safety profile aligns with each drug’s known risks, which may ease approval. However, Trodelvy’s boxed warnings for neutropenia and severe diarrhea could affect reimbursement and treatment protocols.

Future Research Directions

Gilead is studying Trodelvy in more trials, including for PD-L1-negative TNBC patients. This shows confidence in the drug’s broader potential and could reshape TNBC treatment. For more details, see the findings on the Trodelvy Keytruda combination here.

Reference url

Recent Posts

self-care public health
    

The Value of Self-Care in Public Health: Insights and Implications for Europe

🌍 Are we overlooking the power of self-care in Europe’s public health strategy?

The rise of self-care public health is reshaping how minor ailments are managed across the continent, leading to remarkable economic and productivity benefits. With annual savings of €36 billion and lifestyle improvements for consumers, self-care is proving to be a game-changer for healthcare systems.

Explore how embracing self-care can alleviate pressure on healthcare providers and enhance individual well-being. Dive into the full article to discover the implications for health economics and public policy!

#SyenzaNews #HealthEconomics #HealthcarePolicy

pharma ad spending trends
     

Pharma Ad Spending Trends: Insights from the Top 10 Drug Advertisers of 2024

💡 Are you curious about the latest pharma advertising trends and how they reshape healthcare marketing?

In 2024, pharmaceutical companies are significantly increasing their budgets for direct-to-consumer (DTC) campaigns. This shift not only enhances visibility in an AI-driven landscape but also empowers patients with vital health information. Discover how leading brands are strategizing for success amidst stiff competition!

Dive into the full article to explore key insights about the top advertisers and the evolving landscape of pharma marketing.

#SyenzaNews #Pharmaceuticals #DigitalTransformation #Ai

Dutch Health Disruption
     

Dutch Health Disruption: Reimagining Care with Social Entrepreneurship

🔍 Are we ready to rethink our healthcare system for a sustainable future?

Michel van Schaik, Director of Healthcare at Rabobank, argues that the traditional Dutch health model is no longer viable. In his recent article, he advocates for innovative solutions outside the conventional framework, emphasizing community-based initiatives and prevention over treatment to address escalating costs and workforce shortages.

Dive into his vision for a society that prioritizes well-being and citizen collaboration by 2040. Explore the transformative ideas that could redefine our approach to health!

#SyenzaNews #HealthcareInnovation #HealthEconomics

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.